HIV-ASSOCIATED CO-MORBIDITIES: Edited by Morris Schambelan and Todd T. BrownRecent advances in HIV-associated chronic lung disease clinical researchKunisaki, Ken M.a,bAuthor Information aMinneapolis Veterans Affairs Healthcare System bUniversity of Minnesota, Minneapolis, Minnesota, USA Correspondence to Ken M. Kunisaki, MD, MS, Associate Professor of Medicine, Minneapolis VA Healthcare System, Pulmonary, Critical Care, and Sleep (111N), One Veterans Drive, Minneapolis, Minnesota 55417, USA. Tel: +1 (612) 467 4400; fax: +1 (612) 727 5634; e-mail: [email protected] Current Opinion in HIV and AIDS: May 2021 - Volume 16 - Issue 3 - p 156-162 doi: 10.1097/COH.0000000000000679 Buy Metrics Abstract Purpose of review To highlight recently published, clinically focused research on chronic lung disease in adult persons with human immunodeficiency virus-1 (HIV) (PWH). Recent findings Chronic lung disease was the most common comorbidity in hospitalized PWH in New York and second-most common condition in ambulatory PWH in Canada. The elevated risk of chronic obstructive pulmonary disease in PWH has been widely recognized, but PWH are also at higher risk for asthma and worse asthma outcomes. Expanded assessments of lung structure and function, such as single-breath diffusing capacity of carbon monoxide (DLCO), exhaled nitric oxide (FeNO), and chest computed tomography (CT) have provided new insights into HIV effects on the lungs. New biomarker analyses are emerging, but further studies are needed to validate predictive biomarkers for chronic lung disease in PWH. Clinical trials addressing chronic lung disease in PWH are few in number. Summary Chronic lung disease is a common and high-impact comorbidity among PWH. Future studies should collect more comprehensive lung assessments such as DLCO, FeNO, and chest CT in order to better phenotype lung derangements in HIV. Clinical trials are desperately needed to reduce the rising burden of chronic lung disease in PWH. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.